查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593035

靜脈注射免疫球蛋白市場：按適應症、劑型和最終用戶分類 - 全球預測 2025-2030

Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年靜脈注射免疫球蛋白市場價值為12.5億美元，預計到2024年將達到13.3億美元，複合年成長率為6.92%，到2030年將達到19.9億美元。

靜脈注射免疫球蛋白 (IVIG) 療法涉及向患者施用抗體組合，主要用於治療多種免疫力缺乏和自體免疫疾病。 IVIG在原發性免疫力缺乏、慢性脫髓鞘多發性神經炎、甚至某些神經系統疾病的治療中的需求和應用凸顯。最終用途範圍從醫院和診所到居家醫療，凸顯了其多功能的醫療應用。 IVIG 市場主要是由自體免疫疾病盛行率上升以及通常更容易受到此類疾病影響的老年人口不斷增加所推動的。此外，製造技術的進步和免疫球蛋白治療意識的提高也推動了市場的成長。該市場的最新機會集中在開拓國家，這些國家的醫療基礎設施有所改善，生物製藥研究投資增加。利用這些機會的建議包括探索與醫療保健提供者的策略聯盟和夥伴關係，以及加強分銷網路以確保廣泛的產品覆蓋範圍。然而，市場面臨高昂的治療成本、嚴格的法律規範以及與 IVIG 治療相關的潛在副作用（例如過敏反應）等限制。漫長而複雜的製造流程所導致的供應限制也帶來了挑戰。在技​​術創新方面，個人化醫療和新配方開發等領域具有顯著的業務成長潛力。此外，探索替代的遞送方法，例如皮下免疫球蛋白，也可能提供競爭優勢。 IVIG 市場競爭激烈且研究密集型，其特點是持續的產品開發和嚴格遵守監管標準。因此，有效地將紮實的研究、策略夥伴關係和深思熟慮的市場擴張結合起來的公司可能會在這個不斷變化的環境中取得成功。

主要市場統計
基準年[2023] 12.5億美元
預測年份 [2024] 13.3億美元
預測年份 [2030] 19.9億美元
複合年成長率（%） 6.92%

市場動態：快速發展的靜脈免疫球蛋白市場的關鍵市場靜脈注射

供需的動態交互作用正在改變靜脈注射免疫球蛋白市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性脫髓鞘多發性神經炎(CIDP) 和低丙種球蛋白血症的盛行率迅速增加
    • 老年人口和血友病患者顯著增加
    • 靜脈注射免疫球蛋白產品的仿單標示外使用增加
  • 市場限制因素
    • 政府對靜脈注射免疫球蛋白產品的使用有嚴格的規定
  • 市場機會
    • 免疫球蛋白生產改良技術的出現
    • 靜脈注射免疫球蛋白產品核准數量不斷增加
  • 市場挑戰
    • 靜脈注射免疫球蛋白產品相關副作用的高風險

波特五力：駕馭靜脈注射免疫球蛋白市場的策略工具

波特的五力框架是了解靜脈注射免疫球蛋白市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對靜脈注射免疫球蛋白市場的影響

外部宏觀環境因素在塑造靜脈注射免疫球蛋白市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解靜脈注射免疫球蛋白市場的競爭狀況

靜脈注射免疫球蛋白市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣靜脈注射免疫球蛋白市場供應商的績效評估

FPNV定位矩陣是評估靜脈注射市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃靜脈注射免疫球蛋白市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，靜脈注射免疫球蛋白市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性脫髓鞘多發性神經炎(CIDP) 和低丙種球蛋白血症的盛行率迅速增加
      • 老年人口和血友病患者顯著增加
      • 靜脈注射免疫球蛋白產品中仿單標示外適應症的使用增加
    • 抑制因素
      • 政府對靜脈注射免疫球蛋白產品的使用有嚴格的規定
    • 機會
      • 免疫球蛋白生產改良技術的出現
      • 靜脈注射免疫球蛋白產品核可數量增加
    • 任務
      • 靜脈注射免疫球蛋白產品相關副作用的高風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章靜脈注射免疫球蛋白市場依適應症分類

  • 原發性免疫力缺乏
  • 繼發性免疫力缺乏缺陷

第7章靜脈注射免疫球蛋白市場：依形式

  • 液體IVIG
  • 凍乾IVIG

第8章靜脈注射免疫球蛋白市場：依最終使用者分類

  • 居家照護設施
  • 醫院/診所

第9章北美及南美靜脈注射免疫球蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太靜脈注射免疫球蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲靜脈注射免疫球蛋白市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ADMA Biologics, Inc.
  • Baxter International, Inc.
  • Bayer HealthCare LLC
  • Biotest AG by Grifols SA
  • CSL Behring
  • Johnson & Johnson Services, Inc.
  • Kedrion SpA
  • LFB Biotechnologies
  • Octapharma AG
  • Option Care Health, Inc.
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market was valued at USD 1.25 billion in 2023, expected to reach USD 1.33 billion in 2024, and is projected to grow at a CAGR of 6.92%, to USD 1.99 billion by 2030.

Intravenous Immunoglobulin (IVIG) therapy involves administering a mixture of antibodies to patients, primarily used for treating a myriad of immune deficiencies and autoimmune diseases. The necessity and application of IVIG are underscored in the treatment of conditions such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and even in certain neurological disorders. The end-use scope ranges from hospitals and clinics to homecare settings, highlighting its versatile medical application. The market for IVIG is primarily driven by the rising prevalence of autoimmune disorders and a growing geriatric population, which generally presents a higher susceptibility to such medical conditions. Additionally, advancements in production technology and increasing awareness about immunoglobulin therapies foster market growth. The latest opportunities within the market are centered around untapped emerging economies with improving healthcare infrastructure and increasing investment in biopharmaceutical research. Recommendations to capitalize on these opportunities include exploring strategic alliances and partnerships with healthcare providers and enhancing the distribution network to ensure wider product reach. However, the market faces limitations such as high treatment costs, stringent regulatory frameworks, and potential side effects associated with IVIG therapies, such as allergic reactions. Challenges also emerge from supply constraints due to the lengthy and complex production process. In terms of innovation, areas such as personalized medicine and new formulation developments hold potential for substantial business growth. Additionally, research into alternative delivery methods, like subcutaneous immunoglobulin, could provide a competitive edge. The nature of the IVIG market is highly competitive and research-intensive, characterized by continuous product development and strict adherence to regulatory standards. Consequently, companies that effectively combine robust research, strategic partnerships, and thoughtful market expansions are likely to thrive in the evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 1.25 billion
Estimated Year [2024] USD 1.33 billion
Forecast Year [2030] USD 1.99 billion
CAGR (%) 6.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
    • Significant rise in geriatric population and number of hemophilic patients
    • Rising use of off-label indications in intravenous immunoglobulin products
  • Market Restraints
    • Stringent government regulations toward the use of intravenous immunoglobulin products
  • Market Opportunities
    • Emergence of improved technologies in immunoglobulin production
    • Increasing number of intravenous immunoglobulin product approvals
  • Market Challenges
    • High risk of side effects associated with intravenous immunoglobulin products

Porter's Five Forces: A Strategic Tool for Navigating the Intravenous Immunoglobulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intravenous Immunoglobulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intravenous Immunoglobulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intravenous Immunoglobulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intravenous Immunoglobulin Market

A detailed market share analysis in the Intravenous Immunoglobulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intravenous Immunoglobulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intravenous Immunoglobulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intravenous Immunoglobulin Market

A strategic analysis of the Intravenous Immunoglobulin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, Inc., Baxter International, Inc., Bayer HealthCare LLC, Biotest AG by Grifols S.A., CSL Behring, Johnson & Johnson Services, Inc., Kedrion S.p.A., LFB Biotechnologies, Octapharma AG, and Option Care Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Intravenous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Primary Immunodeficiency and Secondary Immunodeficiency.
  • Based on Form, market is studied across Liquid IVIG and Lyophilized IVIG.
  • Based on End-User, market is studied across Homecare Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
      • 5.1.1.2. Significant rise in geriatric population and number of hemophilic patients
      • 5.1.1.3. Rising use of off-label indications in intravenous immunoglobulin products
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent government regulations toward the use of intravenous immunoglobulin products
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of improved technologies in immunoglobulin production
      • 5.1.3.2. Increasing number of intravenous immunoglobulin product approvals
    • 5.1.4. Challenges
      • 5.1.4.1. High risk of side effects associated with intravenous immunoglobulin products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intravenous Immunoglobulin Market, by Indication

  • 6.1. Introduction
  • 6.2. Primary Immunodeficiency
  • 6.3. Secondary Immunodeficiency

7. Intravenous Immunoglobulin Market, by Form

  • 7.1. Introduction
  • 7.2. Liquid IVIG
  • 7.3. Lyophilized IVIG

8. Intravenous Immunoglobulin Market, by End-User

  • 8.1. Introduction
  • 8.2. Homecare Facilities
  • 8.3. Hospitals & Clinics

9. Americas Intravenous Immunoglobulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Intravenous Immunoglobulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Intravenous Immunoglobulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ADMA Biologics, Inc.
  • 2. Baxter International, Inc.
  • 3. Bayer HealthCare LLC
  • 4. Biotest AG by Grifols S.A.
  • 5. CSL Behring
  • 6. Johnson & Johnson Services, Inc.
  • 7. Kedrion S.p.A.
  • 8. LFB Biotechnologies
  • 9. Octapharma AG
  • 10. Option Care Health, Inc.

LIST OF FIGURES

  • FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRAVENOUS IMMUNOGLOBULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023